TABLE 2.
Tissued | % Positive tissues for treatment group (unless stated otherwise) |
|||
---|---|---|---|---|
Oral | i.p. | Oral/DXM | Oral/M | |
Jejunum + LN (proximal, mid-, and distal)b | 54 | 25 | 42 | 67 |
Ileum + LN (proximal, mid-, and distal)c | 17 | 25 | 17 | 50 |
Duodenum + LN | 50 | 50 | 38 | 50 |
Ileocecal valve | 50 | 100 | 50 | 67 |
Ileocecal LN | 25 | 50 | 0 | 33 |
Spleen | 50 | 100 | 50 | 33 |
Iliac LN | 75 | 50 | 50 | 33 |
Spiral colon + LN | 63 | 25 | 38 | 50 |
Transcending colon + LN | 13 | 13 | 25 | 50 |
Descending colon + LN | 25 | 0 | 13 | 17 |
Avg no. of positive tissue sites | 10.3 | 8.5 | 9.5 | 15 |
Avg no. of tissues with lesions | 19 | 8 | 31 | 15 |
The total number of tissue sites sampled per calf was 22.
Three sections of the jejunum (proximal, mid-, and distal sections) plus three associated lymph nodes (n = 6) were sampled.
Three sections of the ileum (proximal, mid-, and distal sections) plus one associated lymph node (n = 4) were sampled.
Tissue + LN, the lymph node (LN) associated with that tissue site was also collected (n = 2 tissue sites).